Li-Zhou Fang^*, Jian-Qing Zhang^*, Ling Liu^*, Wei-Ping Fu^*, Jing-Kui Shu^*, Jia-Gang Feng^*, Xiao Liang^†

Oncology Research, Vol.25, No.5, pp. 819-829, 2017, DOI:10.3727/096504016X14772349843854

Abstract Cancer stem cells (CSCs) are responsible for tumorigenesis and recurrence, so targeting CSCs is an effective method to potentially cure cancer. BTB/POZ domain-containing protein 7 (Btbd7) has been found in various cancers, including lung cancer and liver cancer, but the role of Btbd7 in non-small cell lung cancer (NSCLC), CSC self-renewal, and chemoresistance is still unknown. Therefore, in this study we found that the ratio of tumor sphere formation and stem cell transcription factors in CD133⁺ cells was dramatically enhanced compared to parental cells, which indicated successful sorting of CD133⁺ cells from A549. Meanwhile, Btbd7 and More >

Qifang Long^*, Weipei Zhu^*, Jundong Zhou^†, Jinchang Wu^†, Weixian Lu^‡, Cui Zheng^‡, Dongmei Zhou^‡, Ling Yu^‡, Ru Yang^‡

Oncology Research, Vol.25, No.4, pp. 595-603, 2017, DOI:10.3727/096504016X14765492198706

Abstract Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide. Cancer stem cells (CSCs) have been identified in ovarian cancer and other malignant tumors as a small population of cells that are capable of self-renewal and multidifferentiation. CD133⁺ ovarian CSCs have been reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged as one of the most promising therapeutic markers for ovarian cancer treatment. In the current study, we constructed a recombinant adenovirus Cre/loxP regulation system to selectively introduce truncated Bid (tBid) expression specifically… More >